Equity Profile

DYN

Dyne Therapeutics, Inc.

Health CareBiotechnology$3.2B

Jul27Mon

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Dyne Therapeutics, Inc. is a biotechnology company focused on developing therapies for serious diseases using its proprietary technology....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of a company's profitability and will help gauge how well Dyne is managing its expenses relative to its revenues.

N/A

Revenue Growth

Revenue growth is essential for assessing the company’s ability to expand its market presence and validate its business model.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

DYN Q2-2026 Earnings Preview

Context

Company Snapshot

Dyne Therapeutics, Inc. is a biotechnology company focused on developing therapies for serious diseases using its proprietary technology. Operating in the health care sector, Dyne aims to address unmet medical needs, which is crucial as the demand for innovative treatments continues to grow.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

-5.31%

Avg Stock Reaction

+2.20%

Last Quarter Recap

In Q1 2026, Dyne reported an EPS of -$0.73, slightly beating expectations. The stock reacted positively, gaining 4.83% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Dyne's upcoming earnings are uncertain due to the lack of analyst estimates and management guidance. Investors are keenly watching for any signs of revenue growth or advancements in their product pipeline.

Bull Case

If Dyne demonstrates significant progress in its research and development efforts, it could lead to strong revenue growth and a positive market reaction.

Bear Case

Conversely, if the company fails to show adequate progress or reports higher-than-expected losses, it could lead to a negative reaction from investors.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the reported EPS for Q2 2026?

The EPS figure will be crucial in determining the company's profitability and could significantly impact investor sentiment.

How much has Dyne invested in R&D this quarter?

R&D spending is vital for a biotech firm, and insights into this could indicate the company's commitment to future growth and innovation.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Dyne's potential for revenue growth based on recent advancements in its product pipeline, which could lead to better-than-expected results.

Supporting Evidence

The company's recent EPS surprise history suggests a trend of beating expectations.

Options pricing indicates a high level of anticipated volatility, which may reflect investor optimism not captured in consensus estimates.

Key Risk

If R&D spending shows a significant increase, it could signal stronger future growth, contradicting cautious market expectations.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around Dyne's ability to manage expenses while advancing its product pipeline.

Bull Confirmed If

A reported EPS of -$0.60 or better would confirm the bull case, indicating improved cost management and potential revenue growth.

Bear Confirmed If

An EPS worse than -$0.80 would confirm the bear case, suggesting ongoing challenges in profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±35.44%

Historical Avg

±6.0%

Pricing rich

The options market is pricing in a significant move, indicating that investors expect volatility around the earnings report.

Options are pricing ±35.4% while DYN has averaged ±6.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

60.5%

Calls (4K)P/C Ratio: 1.91Puts (5K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$25.5M

1,282,115 sh

2 insiders

Net

$25.5M

Net selling

Most Active Insiders· 23 open-market trades

Insider

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Dyne beats expectations, history suggests the stock could rise by around 5.96%, confirming a positive outlook for future growth.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction as investors await further clarity on future guidance.

Miss

Should Dyne miss expectations, history suggests a potential decline of approximately 9.27%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on ongoing clinical trials and their expected timelines.
2Any commentary on partnerships or collaborations that could enhance product development.
3Insights into cost management strategies and their impact on future EPS.
4Details on market demand for Dyne's therapies and any new customer acquisitions.
5Management's outlook on the competitive landscape and how Dyne plans to differentiate itself.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aon plc

Company Snapshot

Dyne Therapeutics, Inc. is a biotechnology company focused on developing therapies for serious diseases using its proprietary technology....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of a company's profitability and will help gauge how well Dyne is managing its expenses relative to its revenues.

N/A

Revenue Growth

Revenue growth is essential for assessing the company’s ability to expand its market presence and validate its business model.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

DYN Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

-5.31%

Avg Stock Reaction

+2.20%

Last Quarter Recap

In Q1 2026, Dyne reported an EPS of -$0.73, slightly beating expectations. The stock reacted positively, gaining 4.83% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Dyne demonstrates significant progress in its research and development efforts, it could lead to strong revenue growth and a positive market reaction.

Bear Case

Conversely, if the company fails to show adequate progress or reports higher-than-expected losses, it could lead to a negative reaction from investors.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the reported EPS for Q2 2026?

The EPS figure will be crucial in determining the company's profitability and could significantly impact investor sentiment.

How much has Dyne invested in R&D this quarter?

R&D spending is vital for a biotech firm, and insights into this could indicate the company's commitment to future growth and innovation.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Dyne's potential for revenue growth based on recent advancements in its product pipeline, which could lead to better-than-expected results.

Supporting Evidence

The company's recent EPS surprise history suggests a trend of beating expectations.

Options pricing indicates a high level of anticipated volatility, which may reflect investor optimism not captured in consensus estimates.

Key Risk

If R&D spending shows a significant increase, it could signal stronger future growth, contradicting cautious market expectations.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around Dyne's ability to manage expenses while advancing its product pipeline.

Bull Confirmed If

A reported EPS of -$0.60 or better would confirm the bull case, indicating improved cost management and potential revenue growth.

Bear Confirmed If

An EPS worse than -$0.80 would confirm the bear case, suggesting ongoing challenges in profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±35.44%

Historical Avg

±6.0%

Pricing rich

The options market is pricing in a significant move, indicating that investors expect volatility around the earnings report.

Options are pricing ±35.4% while DYN has averaged ±6.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

60.5%

Calls (4K)P/C Ratio: 1.91Puts (5K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$25.5M

1,282,115 sh

2 insiders

Net

$25.5M

Net selling

Most Active Insiders· 23 open-market trades

Insider

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Dyne beats expectations, history suggests the stock could rise by around 5.96%, confirming a positive outlook for future growth.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction as investors await further clarity on future guidance.

Miss

Should Dyne miss expectations, history suggests a potential decline of approximately 9.27%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on ongoing clinical trials and their expected timelines.
2Any commentary on partnerships or collaborations that could enhance product development.
3Insights into cost management strategies and their impact on future EPS.
4Details on market demand for Dyne's therapies and any new customer acquisitions.
5Management's outlook on the competitive landscape and how Dyne plans to differentiate itself.